Overview

Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Status:
Unknown status

Trial end date:
2020-12-31

Target enrollment:

Participant gender:

Summary

To observe the efficacy and safety of Chidamide combined with prednisone, cyclophosphamide, etoposide and methotrexate in relapsed or refractory PTCL.

Phase:

Phase 2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Cyclophosphamide
Etoposide
Etoposide phosphate
Methotrexate
Prednisone